Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Efficacy, Safety, and Tolerability of Oxcarbazepine Monotherapy in Children With Partial Seizures

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00275912
Recruitment Status : Completed
First Posted : January 12, 2006
Last Update Posted : February 23, 2017
Information provided by (Responsible Party):

Brief Summary:
This study is aimed to collect additional data regarding the efficacy in reducing the frequency of partial seizures, as well as the safety and tolerability, of oxcarbazepine monotherapy in children.

Condition or disease Intervention/treatment Phase
Epilepsy, Partial Seizures Drug: Oxcarbazepine Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A 24-week Prospective Open-label Multicenter Study to Evaluate the Effect on Seizure Frequency, Safety and Tolerability of Oxcarbazepine Monotherapy in Children With Partial Seizures
Actual Study Start Date : September 11, 2006
Actual Primary Completion Date : September 28, 2007
Actual Study Completion Date : September 28, 2007

Primary Outcome Measures :
  1. Epileptic activity at electroencephalography in rest
  2. Flash light and hyperventilation test with electroencephalography
  3. Frequency of epileptic episodes according to patient's diary
  4. Electrocardiogram analysis for rhythm and conduction
  5. Blood test for sodium, hepatic enzymes and blood cells

Secondary Outcome Measures :
  1. Tolerability and safety of 24 week's treatment with oxcarbazepine monotherapy in children with partial seizures
  2. Rate of patients with total and partial control of epilepsy
  3. Rate of patients requiring additional antiepileptic drugs

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   6 Months to 17 Years   (Child)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • males and females, 6 months - 17 years of age;
  • diagnosis of epilepsy, partial seizures;
  • ineffective or intolerable present therapy with 1 antiepileptic drug, or none of previous antiepileptic therapy

Exclusion Criteria:

  • progressive lesion of brain revealed by CT/MRI that performed no earlier than 2 years prior to screening;
  • non-epileptic seizures;
  • drug or alcohol dependence during a year prior to screening;

Other protocol-defined inclusion/exclusion criteria may apply.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00275912

Layout table for location information
Russian Federation
Regional Pediatric Clinical Hospital №1 EkaterinburgRegional Pediatric Clinical Hospital №1
Ekaterinburg, Russian Federation
Moscow Scientific Research Institute of Pediatrics and Pediatric Surgery
Moscow, Russian Federation
Russian State Medical University clinically based on Russian Pediatric Clinical Hospital
Moscow, Russian Federation
Scientific-practical centre of children treatment suffering from craniofacial malformation and congenital pathology of nervous system
Moscow, Russian Federation
St. Petersburg State Pediatrics Medical Academy
St Petersburg, Russian Federation
Sponsors and Collaborators
Layout table for investigator information
Study Chair: Novartis Pharmaceuticals Novartis Pharmaceuticals

Additional Information:
Layout table for additonal information
Responsible Party: Novartis Identifier: NCT00275912    
Other Study ID Numbers: CTRI476BRU02
First Posted: January 12, 2006    Key Record Dates
Last Update Posted: February 23, 2017
Last Verified: February 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Epilepsies, Partial
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms
Voltage-Gated Sodium Channel Blockers
Sodium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Cytochrome P-450 CYP3A Inducers
Cytochrome P-450 Enzyme Inducers